Sounds to me like QSAM is continuing to add heavy hitters to their board of directors and development team.
Dr. Charles L Link definitely qualifies. He's been active in multiple biotech companies and has been a part of bringing numerous drugs to market. He will also serve as the companies "Medical Director."
Here's the Dr. Baum and Company think about Dr. Link:
“Chuck brings extensive experience managing critical research and development programs, leading breakthrough drug approval efforts, and creating significant shareholder value for both publicly-traded and private companies,” said Douglas R. Baum, the Company’s CEO and Co-Founder. “As we enter our next phase of growth, we expect that Chuck’s corporate leadership and drug development expertise will be critical components to driving our success.”
I can't imagine a more qualified or potentially beneficial person to bring on board.
And what does our newest Director, Dr. Link think about CycloSam, QSAM's initial drug candidate??
“The Company’s primary drug candidate, CycloSam® (Samaium-153 DOTMP), shows great promise for treating several highly underserved oncological needs, including potentially primary bone cancers mostly affecting children and young adults. I’m excited about the opportunity to help the Company advance its strategy and development plans as we enter clinical trials this year.”